Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Emergence 2026
12 slides from Amplia Therapeutics's conference presentation, Feb 18, 2026
Slide 1: ASX Release: Conference Presentation
18 FEBRUARY 2026 ASX RELEASE CONFERENCE PRESENTATION Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX; OTCQB:INNMF), (“Amplia” or the “Company”) announces that Amplia’s COO Dr Rhiannon Jones is presenting today at the For personal use only Emergence 2026 conference, being held in Sydney,
Slide 2: About Amplia and Narmafotinib
fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and Link edIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing atten
Slide 3: Targeting Pancreatic Cancer and Beyond
For personal use only TARGETING PANCREATIC CANCER AND BEYOND February 2026 ampliatx.com | @ampliatx ASX: ATX| OTCQB: INNMF 1
Slide 4: Disclaimer
DISCLAIMER This presentation (Presentation) contains summary information about Amplia Therapeutics market, regulatory and other relevant environments that will exist and affect Amplia’s business and Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 31 operat
Slide 5: Pancreatic Cancer: A devastating disease with limited treatment options
PANCREATIC CANCER A devastating disease with limited treatment options 67,530 estimated new pancreatic For personal use only 8th cancer cases in 2026 most commonly diagonsed in 2025 52,740 estimated deaths from 3rd pancreatic cancer in 2026 most common cause of death from cancer in 2025 3% Progressi
Slide 6: A Fibrotic Shield
A FIBROTIC SHIELD Amplifying existing cancer treatments by reducing the fibrotic barrier that makes cancers difficult to treat chemotherapy For personal use only NARMAFOTINIB Cancer Associated Narmafotinib acts to Both narmafotinib Fibroblasts produce a reduce the fibrous and the dense fibrous matri
Slide 7: The ACCENT Trial
THE ACCENT TRIAL Improving treatment options for metastatic pancreatic cancer Safety Narmafotinib + Gem/Abr Gem/Abr Confirmed Overall Response 40 Complete Response Partial Response Stable Disease For personal use only Progressive Disease Not evaluable 30 Narmafotinib + Gem/Abr Gem/Abr 0 20 40 60 80
Slide 8: Peter's Story
PETER’S STORY An amazing outcome for a dreadful disease Confirmed Partial Response For personal use only Surgery to remove remaining tumour and metastases No live tumour cells detected in removed tissue Pathological Complete Response 6
Slide 9: Opportunities
OPPORTUNITIES Overcoming other difficult-to-treat cancers Cancers Combinations For personal use only Ovarian Chemotherapies Head and Neck New Targeted Drugs Liver Cell Therapies Lung Antibody Therapies Gastric Radiation 7
Slide 10: Key Milestones
KEY MILESTONES Upcoming events 2029 2028 For personal use only 2027 Licensing Deal Regional Licensing or Phase 2b/3 Pancreatic Partnering Deal Cancer Trial Commences AMPLICITY Part B commences 2026 Ovarian Cancer Trial Commences (potential) ACCENT Trial Data 8
Slide 11: A Record of Success
A RECORD OF SUCCESS The team to progress this project Broad experience from leading pharma and biotech companies For personal use only Developed drugs that have made it to market 9
Slide 12: Thank You
For personal use only THANK YOU Chris Burns PhD GAICD FAHMS Rhiannon Jones PhD GAICD CEO and MD COO chris@ampliatx.com rhiannon@ampliatx.com Amplia Therapeutics Limited ASX: ATX| OTCQB: INNMF info@ampliatx.com ampliatx.com